Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials

Baoxing Liu, Yacong Bo, Kunlun Wang, Yang Liu, Xiance Tang, Yan Zhao, Erjiang Zhao and Ling Yuan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:20410-20417. https://doi.org/10.18632/oncotarget.14669

Metrics: PDF 1900 views  |   HTML 2255 views  |   ?  


Baoxing Liu1,*, Yacong Bo2,*, Kunlun Wang1, Yang Liu1, Xiance Tang1, Yan Zhao1, Erjiang Zhao1 and Ling Yuan1

1 Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, Henan, China

2 Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, China

* These authors have contributed equally to this work

Correspondence to:

Ling Yuan, email:

Keywords: neoadjuvant concurrent chemoradiotherapy; esophageal cancer; overall survival; R0 resection rate; progression-free survival

Received: October 05, 2016 Accepted: January 09, 2017 Published: January 15, 2017


Background: The long-term survival benefit of concurrent neoadjuvant chemoradiotherapy in patients with resectable esophageal cancer remains controversial. In the present study, we conducted a meta-analysis to assess these effectiveness.

Methods: We searched for most relevant studies published up to the end of August 2016, using Pubmed and web of knowledge. And additional articles were identified from previous meta-analysis. The hazard ratio (HR, for overall survival and progression free survival) or risk ratio (RR, for R0 resection) with its corresponding 95 % confidence interval (CI) were used to assess the pooled effect.

Results: Twelve articles including 1756 patients were included in the meta-analysis. Concurrent neoadjuvant chemoradiotherapy followed by surgery was associated with significantly improved overall survival (HR=0.76 , 95% CI= 0.68-0.86), progression survival (HR =0.69, 95% CI= 0.59-0.81), and R0 resection rate(RR =1.17, 95% CI= 1.03-1.33). Subgroup analysis suggested that concurrent neoadjuvant chemoradiotherapy could improve overall survival outcome for squamous cell carcinoma (HR=0.73, 95%CI=0.61-0.88) but not those for adenocarcinoma (HR=0.72, 95%CI=0.48-1.04).

Conclusion: Our findings suggested that concurrent neoadjuvant chemoradiotherapy was associated with a significant survival benefit in patients with esophageal cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14669